Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis

Mohanraj Rajesh, Partha Mukhopadhyay, Sándor Bátkai, Grzegorz Godlewski, György Haskó, Lucas Liaudet, Pál Pacher

Research output: Contribution to journalArticlepeer-review

66 Citations (Scopus)


Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme which plays an important role in regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP are being considered as treatment for cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation, and were also reported to be protective against untoward effects exerted by certain anticancer drugs. Here we show that pharmacological inhibition of PARP with 3-aminobenzamide or PJ-34 dose-dependently reduces VEGF-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. These results suggest that treatment with PARP inhibitors may exert additional benefits in various cancers and retinopathies by decreasing angiogenesis.

Original languageEnglish
Pages (from-to)352-357
Number of pages6
JournalBiochemical and Biophysical Research Communications
Issue number2
Publication statusPublished - Nov 17 2006
Externally publishedYes


  • 3-AB
  • Angiogenesis
  • Migration
  • PJ-34
  • Poly(ADP-ribose) polymerase (PARP)
  • Proliferation
  • Tube formation

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis'. Together they form a unique fingerprint.

Cite this